Traws Pharma advances dual-strike broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks

Traws Pharma

Traws Pharma

TRAW

0.00
  • Traws Pharma advanced a proprietary broad-spectrum antiviral combination targeting ongoing Hantavirus and Ebola outbreaks, with potential utility against Lassa.
  • Program centers on a dual mechanism to deplete host nucleotides, then drive viral RdRp to incorporate nucleoside mimics to halt replication.
  • Both components have prior human safety data as single agents, supporting a lower-dose combination strategy to reduce toxicity risk.
  • Non-clinical studies are underway in validated Hantavirus and Ebola animal models, using BSL-3 and BSL-4 laboratories.
  • Chemical development and manufacturing scale-up is running in parallel to support potential emergency supply, stockpiling, and expedited regulatory engagement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-066623), on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.